Literature DB >> 27084453

MiR-363-3p inhibits the epithelial-to-mesenchymal transition and suppresses metastasis in colorectal cancer by targeting Sox4.

Fayong Hu1, Jiang Min2, Xiaonian Cao1, Liang Liu1, Zongqing Ge1, Junbo Hu1, Xiaolan Li3.   

Abstract

Epithelial-to-mesenchymal transition (EMT) plays an essential role in cancer invasion and metastasis and is associated with tumor recurrence in colorectal cancer (CRC). However, the mechanism that contributes to EMT have not been fully understood in CRC. In the present study, we showed that miR-363-3p was frequently down-regulated in CRC tissue specimens with lymph node metastasis. Moreover, we demonstrated that down-regulation of miR-363-3p promoted CRC cell migration and invasion, and induced EMT in vitro and in vivo, revealing that miR-363-3p playes a potential tumor-suppressive role in CRC. Analysis of the underlying mechanisms revealed that miR-363-3p could regulate Sox4 expression by directly targeting its 3'untranslated region. Down-regulation of miR-363-3p increased Sox4 expression and induced EMT, while overexpression of miR-363-3p decreased Sox4 expression. Taken together, our findings indicate that miR-363-3p is involved in CRC metastasis and functions as a tumor suppressor via negatively regulating Sox4. Therefore, the up-regulation of miR-363-3p in human CRC may have therapeutic benefits.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Epithelial-to-mesenchymal transition; Metastasis; MiR-363-3p; Sox4

Mesh:

Substances:

Year:  2016        PMID: 27084453     DOI: 10.1016/j.bbrc.2016.04.055

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

1.  MiR-212/132 is epigenetically downregulated by SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells.

Authors:  Lin Lin; Zhiwen Wang; Haihong Jin; Hongzhen Shi; Zhihong Lu; Zhenqin Qi
Journal:  Tumour Biol       Date:  2016-11-03

2.  Long noncoding RNA lncBRM facilitates the proliferation, migration and invasion of ovarian cancer cells via upregulation of Sox4.

Authors:  Jie Xi; Jing Feng; Saitian Zeng
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

3.  LncRNA OIP5-AS1 interacts with miR-363-3p to contribute to hepatocellular carcinoma progression through up-regulation of SOX4.

Authors:  Jianchu Wang; Qianli Tang; Libai Lu; Zongjiang Luo; Wenchuan Li; Yuan Lu; Jian Pu
Journal:  Gene Ther       Date:  2020-02-10       Impact factor: 5.250

4.  MicroRNA-363-3p Inhibits the Expression of Renal Fibrosis Markers in TGF-β1-Treated HK-2 Cells by Targeting TGF-β2.

Authors:  Xiangnan Dong; Yang Li; Rui Cao; Honglan Xu
Journal:  Biochem Genet       Date:  2021-02-25       Impact factor: 1.890

5.  MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA.

Authors:  Jia Liu; Qun Li; Rui Li; Peiyou Ren; Su Dong
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 5.942

6.  Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells.

Authors:  Anna Komina; Nadezhda Palkina; Mariya Aksenenko; Seseg Tsyrenzhapova; Tatiana Ruksha
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

Review 7.  Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis.

Authors:  Trung Vu; Pran K Datta
Journal:  Cancers (Basel)       Date:  2017-12-16       Impact factor: 6.639

8.  MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1.

Authors:  Yang Lin; Tianmin Xu; Shunqing Zhou; Manhua Cui
Journal:  Oncotarget       Date:  2017-09-30

9.  SIX4 promotes metastasis via activation of the PI3K-AKT pathway in colorectal cancer.

Authors:  Guodong Li; Fuqing Hu; Xuelai Luo; Junbo Hu; Yongdong Feng
Journal:  PeerJ       Date:  2017-05-30       Impact factor: 2.984

10.  microRNA expression profiles of scar and normal tissue from patients with posterior urethral stricture caused by pelvic fracture urethral distraction defects.

Authors:  Kaile Zhang; Jun Chen; Dongliang Zhang; Lin Wang; Weixin Zhao; David Yun-Te Lin; Rong Chen; Hong Xie; Xiaoyong Hu; Xiaolan Fang; Qiang Fu
Journal:  Int J Mol Med       Date:  2018-02-12       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.